Insider Shareholders with Direct Ownership of Lyell Immunopharma, Inc. (LYEL)
This section provides a comprehensive overview of the insiders with direct ownership of Lyell Immunopharma, Inc. (LYEL). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Lyell Immunopharma, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 1,685,614 | 0 | 4,685,614 $49.5 Million | 3 |
Sep 08, 2022
Added 3.01%
|
|
|
Matthew Lang
Chief Business Officer |
162,500 | 0 | 162,500 $1.72 Million | 2 |
Feb 10, 2025
Added 40.91%
|
| 35,640 | 0 | 35,640 $376,714 | 1 |
Mar 31, 2025
Added 50.0%
|
|
|
Lynn Seely
President and CEO |
712,500 | 797 | 34,828 $368,131 | 5 |
Aug 12, 2025
Reduced 1.15%
|
|
David Shook
Chief Medical Officer |
21,900 | 0 | 21,900 $231,483 | 1 |
Jun 09, 2025
Added 50.0%
|
|
Gary K. Lee
Chief Scientific Officer |
152,500 | 267 | 8,957 $94,675 | 4 |
Aug 12, 2025
Reduced 1.5%
|
|
Stephen J. Hill
Chief Operating Officer |
152,500 | 185 | 8,849 $93,533 | 4 |
Aug 12, 2025
Reduced 1.05%
|
|
Charles W. Newton
Chief Financial Officer |
152,500 | 267 | 8,759 $92,582 | 4 |
Aug 12, 2025
Reduced 1.53%
|